Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X


The role of MET and VEGFR in tumor-bone interactions in metastatic castration-resistant prostate cancer (mCRPC). Cabozantinib’s Phase II randomised discontinuation trial includes an mCRPC cohort.

Go Top